Variability in bioavailability of small molecular tyrosine kinase inhibitors

Cancer Treatment Reviews

Volumn 41, Issue 5, 2015, Pages 412-422

  Herbrink, Maikel ^a   Nuijen, Bastiaan ^a   Schellens, Jan H M ^a,b   Beijnen, Jos H ^a,b  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Bioavailability; Chemotherapy; Pharmacokinetics; Tyrosine kinase inhibitors

Indexed keywords

ABC TRANSPORTER; AFATINIB; ANTACID AGENT; AXITINIB; BOSUTINIB; CABOZANTINIB; CRIZOTINIB; CYTOCHROME P450; DABRAFENIB; DASATINIB; ERLOTINIB; GEFITINIB; IMATINIB; LAPATINIB; NILOTINIB; ORGANIC ANION TRANSPORTER; PAZOPANIB; PONATINIB; PROTEIN TYROSINE KINASE INHIBITOR; REGORAFENIB; RUXOLITINIB; SORAFENIB; SUNITINIB; VANDETANIB; VEMURAFENIB; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR;

ACTIVE TRANSPORT; ACUTE LYMPHOBLASTIC LEUKEMIA; AGING; AREA UNDER THE CURVE; BREAST CANCER; CHILD PUGH SCORE; CHRONIC MYELOID LEUKEMIA; COLORECTAL CANCER; DERMATOFIBROSARCOMA PROTUBERANS; DIFFERENTIATED THYROID CANCER; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EXCRETION; DRUG METABOLISM; DRUG PENETRATION; DRUG SOLUBILITY; DYSPEPSIA; EOSINOPHILIC LEUKEMIA; FOOD; FOOD DRUG INTERACTION; GASTROINTESTINAL DISEASE; GASTROINTESTINAL STROMAL TUMOR; GRAPEFRUIT JUICE; HUMAN; HYPEREOSINOPHILIC SYNDROME; KIDNEY CARCINOMA; KIDNEY METASTASIS; LIVER CELL CARCINOMA; LIVER FAILURE; MELANOMA; MYELODYSPLASTIC SYNDROME; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; NON SMALL CELL LUNG CANCER; PANCREAS CANCER; PANCREATIC NEUROENDOCRINE TUMOR; PASSIVE TRANSPORT; PHARMACOGENETICS; POLYCYTHEMIA VERA; REVIEW; SOFT TISSUE SARCOMA; STOMACH PH; SURFACE AREA; THYROID MEDULLARY CARCINOMA; ANIMAL; BIOAVAILABILITY; NEOPLASMS;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL AVAILABILITY; HUMANS; NEOPLASMS; PROTEIN KINASE INHIBITORS;

EID: 84937511127     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2015.03.005     Document Type: Review

References (200)

1. Kohonen P., Ceder R., Smit I., Hongisto V., Myatt G., Hardy B., et al. Cancer biology, toxicology and alternative methods development go hand-in-hand. Basic Clin Pharmacol Toxicol 2014, 115(1):50-58.
2. Pinne M., Raucy J.L. Advantages of cell-based high-volume screening assays to assess nuclear receptor activation during drug discovery. Expert Opin Drug Discov 2014, 9(6):669-686.
3. Maroun C.R., Rowlands T. The Met receptor tyrosine kinase: a key player in oncogenesis and drug resistance. Pharmacol Ther 2014, 142(3):316-338.
4. Charette N., Vandeputte C., Stärkel P. Ras in digestive oncology: from molecular biology to clinical implications. Curr Opin Oncol 2014, 26(4):454-461.
5. Chieffi P. An overview on new anticancer molecular targets in human testicular germ cell tumors. Rend Lincei 2014, 25(2):221-228.
6. Minuti G., D'Incecco A., Landi L., Cappuzzo F. Protein kinase inhibitors to treat non-small-cell lung cancer. Expert Opin Pharmacother 2014, 15(9):1203-1213.
7. Tyner J.W. Functional genomics for personalized cancer therapy. Sci Transl Med 2014, 6(243).
8. Liu G., Franssen E., Fitch M.I., Warner E. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997, 15(1):110-115.
9. Benjamin L., Cotté F.-E., Philippe C., Mercier F., Bachelot T., Vidal-Trécan G. Physicians' preferences for prescribing oral and intravenous anticancer drugs: a Discrete Choice Experiment. Eur J Cancer 2012, 48(6):912-920.
10. Jibodh R.A., Lagas J.S., Nuijen B., Beijnen J.H., Schellens J.H.M. Taxanes: old drugs, new oral formulations. Eur J Pharmacol 2013, 717(1-3):40-46.
11. European Medicines Agency (EMA). European Public Assessments Reports (EPARs). <>, [accessed 20.8.14]. http://www.ema.europa.eu.
12. US Food and Drug administration (FDA). Product Label Descriptions. <>, [accessed 20.8.14]. http://fda.gov.
13. Administration Australian therapeutic goods. Australian Public Assessment Reports for prescription medicines (AUSPARs). <>, [accessed 20.8.14]. http://tga.gov.au.
14. Hartmann J.T., Haap M., Kopp H.-G., Lipp H.-P. Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects. Curr Drug Metab 2009, 10(5):470-481.
15. Harrison M.R. Pharmacotherapy options in advanced renal cell carcinoma: what role for pazopanib?. Clin Med Insights Oncol 2011, 5:349-364.
16. Rowland M., Tozer T.N. Clinical pharmacokinetics; concepts and applications 1994, Lippincott, Williams & Wilkins, Philadelphia. 3rd ed.
17. Fan J., de Lannoy I.A.M. Pharmacokinetics. Biochem Pharmacol 2014, 87(1):93-120.
18. Hellriegel E.T., Bjornsson T.D., Hauck W.W. Interpatient variability in bioavailability is related to the extent of absorption: implications for bioavailability and bioequivalence studies. Clin Pharmacol Ther 1996, 60(6):601-607.
19. US Food and Drug administration (FDA). Clinical pharmacology and biopharmaceutics reviews0. <>, [accessed 20.8.14]. http://fda.gov.
20. Freiwald M., Schmid U., Fleury A., Wind S., Stopfer P., Staab A. Population pharmacokinetics of afatinib, an irreversible ErbB family blocker, in patients with various solid tumors. Cancer Chemother Pharmacol 2014, 73(4):759-770.
21. Garrett M., Poland B., Brennan M., Hee B., Pithavala Y.K., Amantea M.A. Population pharmacokinetic analysis of axitinib in healthy volunteers. Br J Clin Pharmacol 2014, 77(3):480-492.
22. Hsyu P.-H., Mould D.R., Upton R.N., Amantea M. Pharmacokinetic-pharmacodynamic relationship of bosutinib in patients with chronic phase chronic myeloid leukemia. Cancer Chemother Pharmacol 2013, 71(1):209-218.
23. Hsyu P.-H., Mould D., Abbas R., Pearce S., Amantea M. Abstract A195: a population pharmacokinetic (PPK) model of bosutinib (BOS). Mol Cancer Ther 2011, 10(Supplement 1):A195.
24. Ouellet D., Gibiansky E., Leonowens C., O'Hagan A., Haney P., Switzky J., et al. Population pharmacokinetics of dabrafenib, a BRAF inhibitor: effect of dose, time, covariates, and relationship with its metabolites. J Clin Pharmacol 2014, 54(6):696-706.
25. Fukudo M., Ikemi Y., Togashi Y., Masago K., Kim Y.H., Mio T., et al. Population pharmacokinetics/pharmacodynamics of erlotinib and pharmacogenomic analysis of plasma and cerebrospinal fluid drug concentrations in Japanese patients with non-small cell lung cancer. Clin Pharmacokinet 2013, 52(7):593-609.
26. White-Koning M., Civade E., Geoerger B., Thomas F., Le Deley M.-C., Hennebelle I., et al. Population analysis of erlotinib in adults and children reveals pharmacokinetic characteristics as the main factor explaining tolerance particularities in children. Clin Cancer Res 2011, 17(14):4862-4871.
27. Thomas F., Rochaix P., White-Koning M., Hennebelle I., Sarini J., Benlyazid A., et al. Population pharmacokinetics of erlotinib and its pharmacokinetic/pharmacodynamic relationships in head and neck squamous cell carcinoma. Eur J Cancer 2009, 45(13):2316-2323.
28. Filppula A.M., Neuvonen M., Laitila J., Neuvonen P.J., Backman J.T. Autoinhibition of CYP3A4 leads to important role of CYP2C8 in imatinib metabolism: variability in CYP2C8 activity may alter plasma concentrations and response. Drug Metab Dispos 2013, 41(1):50-59.
29. Yoo C., Ryu M.-H., Ryoo B.-Y., Beck M.Y., Chang H.-M., Lee J.-L., et al. Changes in imatinib plasma trough level during long-term treatment of patients with advanced gastrointestinal stromal tumors: correlation between changes in covariates and imatinib exposure. Invest New Drugs 2012, 30(4):1703-1708.
30. Tanaka C., Yin O.Q.P., Smith T., Sethuraman V., Grouss K., Galitz L., et al. Effects of rifampin and ketoconazole on the pharmacokinetics of nilotinib in healthy participants. J Clin Pharmacol 2011, 51(1):75-83.
31. Pick A.M., Nystrom K.K. Pazopanib for the treatment of metastatic renal cell carcinoma. Clin Ther 2012, 34(3):511-520.
32. Hurwitz H.I., Dowlati A., Saini S., Savage S., Suttle A.B., Gibson D.M., et al. Phase I trial of pazopanib in patients with advanced cancer. Clin Cancer Res 2009, 15(12):4220-4227.
33. Jain L., Woo S., Gardner E.R., Dahut W.L., Kohn E.C., Kummar S., et al. Population pharmacokinetic analysis of sorafenib in patients with solid tumours. Br J Clin Pharmacol 2011, 72(2):294-305.
34. Strumberg D., Clark J.W., Awada A., Moore M.J., Richly H., Hendlisz A., et al. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist. 2007, 12(4):426-437.
35. Mizuno T., Fukudo M., Fukuda T., Terada T., Dong M., Kamba T., et al. The effect of ABCG2 genotype on the population pharmacokinetics of sunitinib in patients with renal cell carcinoma. Ther Drug Monit 2014, 36(3):310-316.
36. Houk B.E., Bello C.L., Kang D., Amantea M. A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients. Clin Cancer Res 2009, 15(7):2497-2506.
37. Martin P., Oliver S., Kennedy S.-J., Partridge E., Hutchison M., Clarke D., et al. Pharmacokinetics of vandetanib: three phase I studies in healthy subjects. Clin Ther 2012, 34(1):221-237.
38. Yu H., Steeghs N., Nijenhuis C.M., Schellens J.H.M., Beijnen J.H., Huitema A.D.R. Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors: focus on the pharmacokinetic targets. Clin Pharmacokinet 2014, 53(4):305-325.
39. Murakami H., Tamura T., Takahashi T., Nokihara H., Naito T., Nakamura Y., et al. Phase I study of continuous afatinib (BIBW 2992) in patients with advanced non-small cell lung cancer after prior chemotherapy/erlotinib/gefitinib (LUX-Lung 4). Cancer Chemother Pharmacol 2012, 69(4):891-899.
40. Marshall J., Shapiro G.I., Uttenreuther-Fischer M., Ould-Kaci M., Stopfer P., Gordon M.S. Phase I dose-escalation study of afatinib, an ErbB family blocker, plus docetaxel in patients with advanced cancer. Future Oncol 2013, 9(2):271-281.
41. Daud A.I., Krishnamurthi S.S., Saleh M.N., Gitlitz B.J., Borad M.J., Gold P.J., et al. Phase I study of bosutinib, a src/abl tyrosine kinase inhibitor, administered to patients with advanced solid tumors. Clin Cancer Res 2012, 18(4):1092-1100.
42. Kurzrock R., Sherman S.I., Ball D.W., Forastiere A.A., Cohen R.B., Mehra R., et al. Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol 2011, 29(19):2660-2666.
43. Mossé Y.P., Lim M.S., Voss S.D., Wilner K., Ruffner K., Laliberte J., et al. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study. Lancet Oncol 2013, 14(6):472-480.
44. Menzies A.M., Long G.V., Murali R. Dabrafenib and its potential for the treatment of metastatic melanoma. Drug Des Devel Ther 2012, 6:391-405.
45. Falchook G.S., Long G.V., Kurzrock R., Kim K.B., Arkenau T.H., Brown M.P., et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 2012, 379(9829):1893-1901.
46. Aplenc R., Blaney S.M., Strauss L.C., Balis F.M., Shusterman S., Ingle A.M., et al. Pediatric phase I trial and pharmacokinetic study of dasatinib: a report from the children's oncology group phase I consortium. J Clin Oncol 2011, 29(7):839-844.
47. Higgins B., Kolinsky K., Smith M., Beck G., Rashed M., Adames V., et al. Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in combination in human non-small cell lung cancer tumor xenograft models. Anticancer Drugs 2004, 15(5):503-512.
48. Togashi Y., Masago K., Fujita S., Hatachi Y., Fukuhara A., Nagai H., et al. Differences in adverse events between 250mg daily gefitinib and 150mg daily erlotinib in Japanese patients with non-small cell lung cancer. Lung cancer 2011, 74(1):98-102.
49. Reardon D.A., Desjardins A., Vredenburgh J.J., Sathornsumetee S., Rich J.N., Quinn J.A., et al. Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma. Neuro Oncol 2008, 10(3):330-340.
50. Lin N.U., Freedman R.A., Ramakrishna N., Younger J., Storniolo A.M., Bellon J.R., et al. A phase I study of lapatinib with whole brain radiotherapy in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer brain metastases. Breast Cancer Res Treat 2013, 142(2):405-414.
51. Bradeen H.A., Eide C.A., O'Hare T., Johnson K.J., Willis S.G., Lee F.Y., et al. Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. Blood 2006, 108(7):2332-2338.
52. Mascarenhas J., Hoffman R. Ruxolitinib: the first FDA approved therapy for the treatment of myelofibrosis. Clin Cancer Res 2012, 18(11):3008-3014.
53. Lankheet N.A.G., Knapen L.M., Schellens J.H.M., Beijnen J.H., Steeghs N., Huitema A.D.R. Plasma concentrations of tyrosine kinase inhibitors imatinib, erlotinib, and sunitinib in routine clinical outpatient cancer care. Ther Drug Monit 2014, 36(3):326-334.
54. Patson B., Cohen R B., Olszanski A.J. Pharmacokinetic evaluation of axitinib. Expert Opin Drug Metab Toxicol 2012, 8(2):259-270.
55. Benet L.Z. The role of BCS (biopharmaceutics classification system) and BDDCS (biopharmaceutics drug disposition classification system) in drug development. J Pharm Sci 2013, 102(1):34-42.
56. Amidon G.L., Lennernäs H., Shah V.P., Crison J.R. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 1995, 12(3):413-420.
57. Lennernäs H., Abrahamsson B. The use of biopharmaceutic classification of drugs in drug discovery and development: current status and future extension. J Pharm Pharmacol 2005, 57(3):273-285.
58. Bergström C.A.S., Andersson S.B.E., Fagerberg J.H., Ragnarsson G., Lindahl A. Is the full potential of the biopharmaceutics classification system reached?. Eur J Pharm Sci 2014, 57:224-231.
59. Australian Therapeutic Goods Administration. Australian Public Assessment Report (AUSPAR) for Ruxolitinib. <>, [accessed 20.8.14]. http://tga.gov.au.
60. Broccatelli F., Cruciani G., Benet L.Z., Oprea T.I. BDDCS class prediction for new molecular entities. Mol Pharm 2012, 9(3):570-580.
61. Wu C.-Y., Benet L.Z. Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res 2005, 22(1):11-23.
62. Macheras P., Karalis V., Valsami G. Keeping a critical eye on the science and the regulation of oral drug absorption: a review. J Pharm Sci 2013, 102(9):3018-3036.
63. Benet L.Z., Broccatelli F., Oprea T.I. BDDCS applied to over 900 drugs. AAPS J 2011, 13(4):519-547.
64. Benet LZ. BDDCS - Its impact and application. 1st MENA Regulatory Conference on bioequivalence, biowaivers, bioanalysis and dissolution, 2013.
65. Noyes A.A., Whitney W.R. The rate of solution of solid substances in their own solutions. J Am Chem Soc 1897, 19(12):930-934.
66. Dressman J.B., Amidon G.L., Reppas C., Shah V.P. Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms. Pharm Res 1998, 15(1):11-22.
67. Jambhekar S.S., Breen P.J. Drug dissolution: significance of physicochemical properties and physiological conditions. Drug Discov Today 2013, 18(23-24):1173-1184.
68. Florence A., Attwood D. Physicochemical principles of pharmacy 2006, Pharmaceutical Press, London. 4rd ed.
69. Sjögren E., Westergren J., Grant I., Hanisch G., Lindfors L., Lennernäs H., et al. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim. Eur J Pharm Sci 2013, 49(4):679-698.
70. Reppas C., Meyer J.H., Sirois P.J., Dressman J.B. Effect of hydroxypropylmethylcellulose on gastrointestinal transit and luminal viscosity in dogs. Gastroenterology 1991, 100(5 Pt 1):1217-1223.
71. Augustijns P., Wuyts B., Hens B., Annaert P., Butler J., Brouwers J. A review of drug solubility in human intestinal fluids: implications for the prediction of oral absorption. Eur J Pharm Sci 2014, 57:322-332.
72. Davis S.S., Hardy J.G., Fara J.W. Transit of pharmaceutical dosage forms through the small intestine. Gut 1986, 27(8):886-892.
73. Lennernas H. Modeling gastrointestinal drug absorption requires more in vivo biopharmaceutical data: experience from in vivo dissolution and permeability studies in humans. Curr Drug Metab 2007, 8(7):645-657.
74. Mitra A., Kesisoglou F. Impaired drug absorption due to high stomach pH: a review of strategies for mitigation of such effect to enable pharmaceutical product development. Mol Pharm 2013, 10(11):3970-3979.
75. Psachoulias D., Vertzoni M., Butler J., Busby D., Symillides M., Dressman J., et al. An in vitro methodology for forecasting luminal concentrations and precipitation of highly permeable lipophilic weak bases in the fasted upper small intestine. Pharm Res 2012, 29(12):3486-3498.
76. US Food and Drug administration (FDA). Chemistry reviews. <>, [accessed 20.8.14]. http://fda.gov.
77. Thomas G. Medicinal chemistry: an introduction 2007, John Wiley and sons, Chichester. 2nd ed.
78. Kumar L., Meena C.L., Pawar Y.B., Wahlang B., Tikoo K., Jain R., et al. Effect of counterions on physicochemical properties of prazosin salts. AAPS PharmSciTech. 2013, 14(1):141-150.
79. Stahl P., Wermuth C. Handbook of pharmaceutical salts: properties, selection and use 2008, Wiley, Hoboken. 1st ed.
80. Einfalt T., Planinsek O., Hrovat K. Methods of amorphization and investigation of the amorphous state. Acta Pharm 2013, 63:305-334.
81. Newman A., Knipp G., Zografi G. Assessing the performance of amorphous solid dispersions. J Pharm Sci 2012, 101(4):1355-1377.
82. Janssens S., Van den Mooter G. Review: physical chemistry of solid dispersions. J Pharm Pharmacol 2009, 61(12):1571-1586.
83. Ouellet D., Grossmann K.F., Limentani G., Nebot N., Lan K., Knowles L., et al. Effects of particle size, food, and capsule shell composition on the oral bioavailability of dabrafenib, a BRAF inhibitor, in patients with BRAF mutation-positive tumors. J Pharm Sci 2013, 102(9):3100-3109.
84. Sheng J.J., Sirois P.J., Dressman J.B., Amidon G.L. Particle diffusional layer thickness in a USP dissolution apparatus II: a combined function of particle size and paddle speed. J Pharm Sci 2008, 97(11):4815-4829.
85. Grohganz H., Priemel P.A., Löbmann K., Nielsen L.H., Laitinen R., Mullertz A., et al. Refining stability and dissolution rate of amorphous drug formulations. Expert Opin Drug Deliv 2014, 11(6):977-989.
86. Lennernäs H. Human in vivo regional intestinal permeability: importance for pharmaceutical drug development. Mol Pharm 2014, 11(1):12-23.
87. Mudie D.M., Amidon G.L., Amidon G.E. Physiological parameters for oral delivery and in vitro testing. Mol Pharm 2010, 7(5):1388-1405.
88. Hu Y.-J., Wang Y.-D., Tan F.-Q., Yang W.-X. Regulation of paracellular permeability: factors and mechanisms. Mol Biol Rep 2013, 40(11):6123-6142.
89. Sugano K., Kansy M., Artursson P., Avdeef A., Bendels S., Di L., et al. Coexistence of passive and carrier-mediated processes in drug transport. Nat Rev Drug Discov 2010, 9(8):597-614.
90. Estudante M., Morais J.G., Soveral G., Benet L.Z. Intestinal drug transporters: an overview. Adv Drug Deliv Rev 2013, 65(10):1340-1356.
91. Varma M.V., Ambler C.M., Ullah M., Rotter C.J., Sun H., Litchfield J., et al. Targeting intestinal transporters for optimizing oral drug absorption. Curr Drug Metab 2010, 11(9):730-742.
92. Shugarts S., Benet L.Z. The role of transporters in the pharmacokinetics of orally administered drugs. Pharm Res 2009, 26(9):2039-2054.
93. Hediger M.A., Romero M.F., Peng J.-B., Rolfs A., Takanaga H., Bruford E.A. The ABCs of solute carriers: physiological, pathological and therapeutic implications of human membrane transport proteins introduction. Pflugers Arch 2004, 447(5):465-468.
94. Vasiliou V., Vasiliou K., Nebert D.W. Human ATP-binding cassette (ABC) transporter family. Hum Genomics 2008, 3(3):281.
95. Zakeri-Milani P., Valizadeh H. Intestinal transporters: enhanced absorption through P-glycoprotein-related drug interactions. Expert Opin Drug Metab Toxicol 2014, 10(6):859-871.
96. Stieger B., Hagenbuch B. Organic anion-transporting polypeptides. Curr Top Membr 2014, 73:205-232.
97. Liu T., Li Q. Organic anion-transporting polypeptides: a novel approach for cancer therapy. J Drug Target 2014, 22(1):14-22.
98. Noguchi K., Katayama K., Sugimoto Y. Human ABC transporter ABCG2/BCRP expression in chemoresistance: basic and clinical perspectives for molecular cancer therapeutics. Pharmgenomics Pers Med 2014, 7:53-64.
99. Liu Y.-H., Di Y.-M., Zhou Z.-W., Mo S.-L., Zhou S.-F. Multidrug resistance-associated proteins and implications in drug development. Clin Exp Pharmacol Physiol 2010, 37(1):115-120.
100. Jani M., Ambrus C., Magnan R., Jakab K.T., Beéry E., Zolnerciks J.K., et al. Structure and function of BCRP, a broad specificity transporter of xenobiotics and endobiotics. Arch Toxicol 2014, 88(6):1205-1248.
101. Bruyère A., Declèves X., Bouzom F., Ball K., Marques C., Treton X., et al. Effect of variations in the amounts of P-glycoprotein (ABCB1), BCRP (ABCG2) and CYP3A4 along the human small intestine on PBPK models for predicting intestinal first pass. Mol Pharm 2010, 7(5):1596-1607.
102. Natarajan K., Xie Y., Baer M.R., Ross D.D. Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance. Biochem Pharmacol 2012, 83(8):1084-1103.
103. Ingelman-Sundberg M. Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. Trends Pharmacol Sci 2004, 25(4):193-200.
104. Brändén G., Sjögren T., Schnecke V., Xue Y. Structure-based ligand design to overcome CYP inhibition in drug discovery projects. Drug Discov Today 2014, 19(7):905-911.
105. De Groot M.J. Designing better drugs: predicting cytochrome P450 metabolism. Drug Discov Today 2006, 11(13-14):601-606.
106. Brunton L., Chabner B. Goodman and Gilman's the pharmacological basis of therapeutics 2011, McGraw-Hill Professional, New York. 12th ed.
107. Thelen K., Dressman J.B. Cytochrome P450-mediated metabolism in the human gut wall. J Pharm Pharmacol 2009, 61(5):541-558.
108. Bock K.W. Homeostatic control of xeno- and endobiotics in the drug-metabolizing enzyme system. Biochem Pharmacol 2014, 90(1):1-6.
109. Zhou S.-F., Liu J.-P., Chowbay B. Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev 2009, 41(2):89-295.
110. Sim S.C., Ingelman-Sundberg M. The Human Cytochrome P450 (CYP) Allele Nomenclature website: a peer-reviewed database of CYP variants and their associated effects. Hum Genomics 2010, 4(4):278.
111. Meech R., Miners J.O., Lewis B.C., Mackenzie P.I. The glycosidation of xenobiotics and endogenous compounds: versatility and redundancy in the UDP glycosyltransferase superfamily. Pharmacol Ther 2012, 134(2):200-218.
112. Rowland A., Miners J.O., Mackenzie P.I. The UDP-glucuronosyltransferases: their role in drug metabolism and detoxification. Int J Biochem Cell Biol 2013, 45(6):1121-1132.
113. Wu B., Kulkarni K., Basu S., Zhang S., Hu M. First-pass metabolism via UDP-glucuronosyltransferase: a barrier to oral bioavailability of phenolics. J Pharm Sci 2011, 100(9):3655-3681.
114. Thomas-Schoemann A., Blanchet B., Bardin C., Noé G., Boudou-Rouquette P., Vidal M., et al. Drug interactions with solid tumour-targeted therapies. Crit Rev Oncol Hematol 2014, 89(1):179-196.
115. Kimura S.-I., Kako S., Wada H., Sakamoto K., Ashizawa M., Sato M., et al. Can grapefruit juice decrease the cost of imatinib for the treatment of chronic myelogenous leukemia?. Leuk Res 2011, 35(1):e11-2.
116. Van Erp N.P., Baker S.D., Zandvliet A.S., Ploeger B.A., den Hollander M., Chen Z., et al. Marginal increase of sunitinib exposure by grapefruit juice. Cancer Chemother Pharmacol 2011, 67(3):695-703.
117. Deangelo D.J. Managing chronic myeloid leukemia patients intolerant to tyrosine kinase inhibitor therapy. Blood Cancer J. 2012, 2:e95.
118. Francis S., Delgoda R. A patent review on the development of human cytochrome P450 inhibitors. Expert Opin Ther Pat 2014, 24(6):699-717.
119. Ingelman-Sundberg M., Sim S.C., Gomez A., Rodriguez-Antona C. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 2007, 116(3):496-526.
120. Zanger U.M., Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther 2013, 138(1):103-141.
121. Martiny V.Y., Miteva M.A. Advances in molecular modeling of human cytochrome P450 polymorphism. J Mol Biol 2013, 425(21):3978-3992.
122. Nie Q., Yang X.-N., An S.-J., Zhang X.-C., Yang J.-J., Zhong W.-Z., et al. CYP1A1*2A polymorphism as a predictor of clinical outcome in advanced lung cancer patients treated with EGFR-TKI and its combined effects with EGFR intron 1 (CA)n polymorphism. Eur J Cancer 2011, 47(13):1962-1970.
123. Klümpen H.-J., Samer C.F., Mathijssen R.H.J., Schellens J.H.M., Gurney H. Moving towards dose individualization of tyrosine kinase inhibitors. Cancer Treat Rev 2011, 37(4):251-260.
124. Pander J., Guchelaar H.J., Gelderblom H. Pharmacogenetics of small-molecule tyrosine kinase inhibitors: optimizing the magic bullet. Curr Opin Mol Ther 2010, 12(6):654-661.
125. Nies A.T., Schwab M., Keppler D. Interplay of conjugating enzymes with OATP uptake transporters and ABCC/MRP efflux pumps in the elimination of drugs. Expert Opin Drug Metab Toxicol 2008, 4(5):545-568.
126. Wooten J.M. Pharmacotherapy considerations in elderly adults. South Med J 2012, 105(8):437-445.
127. Hurria A., Lichtman S.M. Clinical pharmacology of cancer therapies in older adults. Br J Cancer 2008, 98(3):517-522.
128. Christensen E. Prognostic models including the Child-Pugh, MELD and Mayo risk scores - where are we and where should we go?. J Hepatol 2004, 41(2):344-350.
129. Azim H.A., Agbor-Tarh D., Bradbury I., Dinh P., Baselga J., Di Cosimo S., et al. Pattern of rash, diarrhea, and hepatic toxicities secondary to lapatinib and their association with age and response to neoadjuvant therapy: analysis from the NeoALTTO trial. J Clin Oncol 2013, 31(36):4504-4511.
130. Bahirwani R., Reddy K.R. Drug-induced liver injury due to cancer chemotherapeutic agents. Semin Liver Dis 2014, 34(2):162-171.
131. Syvak L.A., Lial'kin S.A., Klimanov M.I., Hubareva H.O., Askol's'kyĭ A.V., Kasap N.V., et al. Hepatotoxicity of cytostatic drugs in treatment of oncology patients. Lik Sprava 2013, 2:14-24.
132. De Mestier L., Manceau G., Neuzillet C., Bachet J.B., Spano J.P., Kianmanesh R., et al. Primary tumor resection in colorectal cancer with unresectable synchronous metastases: a review. World J Gastrointest Oncol 2014, 6(6):156-169.
133. Jamei M., Turner D., Yang J., Neuhoff S., Polak S., Rostami-Hodjegan A., et al. Population-based mechanistic prediction of oral drug absorption. AAPS J 2009, 11(2):225-237.
134. Varum F.J.O., Hatton G.B., Basit A.W. Food, physiology and drug delivery. Int J Pharm 2013, 457(2):446-460.
135. Sjögren E., Abrahamsson B., Augustijns P., Becker D., Bolger M.B., Brewster M., et al. In vivo methods for drug absorption - comparative physiologies, model selection, correlations with in vitro methods (IVIVC), and applications for formulation/API/excipient characterization including food effects. Eur J Pharm Sci 2014, 57:99-151.
136. Kalantzi L., Goumas K., Kalioras V., Abrahamsson B., Dressman J.B., Reppas C. Characterization of the human upper gastrointestinal contents under conditions simulating bioavailability/bioequivalence studies. Pharm Res 2006, 23(1):165-176.
137. Persson E.M., Gustafsson A.-S., Carlsson A.S., Nilsson R.G., Knutson L., Forsell P., et al. The effects of food on the dissolution of poorly soluble drugs in human and in model small intestinal fluids. Pharm Res 2005, 22(12):2141-2151.
138. Bratten J., Jones M.P. Prolonged recording of duodenal acid exposure in patients with functional dyspepsia and controls using a radiotelemetry pH monitoring system. J Clin Gastroenterol 2009, 43(6):527-533.
139. Karhunen L.J., Juvonen K.R., Huotari A., Purhonen A.K., Herzig K.H. Effect of protein, fat, carbohydrate and fibre on gastrointestinal peptide release in humans. Regul Pept 2008, 149(1-3):70-78.
140. Beglinger C., Degen L. Fat in the intestine as a regulator of appetite - role of CCK. Physiol Behav 2004, 83(4):617-621.
141. Wilson C.G. The transit of dosage forms through the colon. Int J Pharm 2010, 395(1-2):17-25.
142. Cvijić S., Parojčić J., Langguth P. Viscosity-mediated negative food effect on oral absorption of poorly-permeable drugs with an absorption window in the proximal intestine: In vitro experimental simulation and computational verification. Eur J Pharm Sci 2014, 61:40-53.
143. Charman W.N., Porter C.J., Mithani S., Dressman J.B. Physiochemical and physiological mechanisms for the effects of food on drug absorption: the role of lipids and pH. J Pharm Sci 1997, 86(3):269-282.
144. Dressman J.B. Comparison of canine and human gastrointestinal physiology. Pharm Res 1986, 3(3):123-131.
145. Abbas R., Hug B.A., Leister C., El Gaaloul M., Chalon S., Sonnichsen D. A phase I ascending single-dose study of the safety, tolerability, and pharmacokinetics of bosutinib (SKI-606) in healthy adult subjects. Cancer Chemother Pharmacol 2012, 69(1):221-227.
146. Devriese L.A., Koch K.M., Mergui-Roelvink M., Matthys G.M., Ma W.W., Robidoux A., et al. Effects of low-fat and high-fat meals on steady-state pharmacokinetics of lapatinib in patients with advanced solid tumours. Invest New Drugs 2014, 32(3):481-488.
147. Ribas A., Zhang W., Chang I., Shirai K., Ernstoff M.S., Daud A., et al. The effects of a high-fat meal on single-dose vemurafenib pharmacokinetics. J Clin Pharmacol 2014, 54(4):368-374.
148. Fass R. Alternative therapeutic approaches to chronic proton pump inhibitor treatment. Clin Gastroenterol Hepatol 2012, 10(4):338-345. (quiz e39-40).
149. Budha N.R., Frymoyer A., Smelick G.S., Jin J.Y., Yago M.R., Dresser M.J., et al. Drug absorption interactions between oral targeted anticancer agents and PPIs: is pH-dependent solubility the Achilles heel of targeted therapy?. Clin Pharmacol Ther 2012, 92(2):203-213.
150. Joensuu H., Roberts P.J., Sarlomo-Rikala M., Andersson L.C., Tervahartiala P., Tuveson D., et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001, 344(14):1052-1056.
151. Smelick G.S., Heffron T.P., Chu L., Dean B., West D.A., Duvall S.L., et al. Prevalence of acid-reducing agents (ARA) in cancer populations and ARA drug-drug interaction potential for molecular targeted agents in clinical development. Mol Pharm 2013, 10(11):4055-4062.
152. Santoni M., Conti A., De Giorgi U., Iacovelli R., Pantano F., Burattini L., et al. Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: a systematic review and meta-analysis of clinical trials. Int J Cancer 2014, 135(4):763-773.
153. Shin J.M., Vagin O., Munson K., Kidd M., Modlin I.M., Sachs G. Molecular mechanisms in therapy of acid-related diseases. Cell Mol Life Sci 2008, 65(2):264-281.
154. Brett S. Science review: the use of proton pump inhibitors for gastric acid suppression in critical illness. Crit Care 2005, 9(1):45-50.
155. Zhang L., Wu F., Lee S.C., Zhao H. PH-dependent drug-drug interactions for weak base drugs: potential implications for new drug development. Clin Pharmacol Ther 2014, 96(2):266-277.
156. Ogawa R., Echizen H. Clinically significant drug interactions with antacids: an update. Drugs 2011, 71(14):1839-1864.
157. Gupta S., Kesarla R., Omri A. Formulation strategies to improve the bioavailability of poorly absorbed drugs with special emphasis on self-emulsifying systems. ISRN Pharm 2013, 2013:848043.
158. Yao M., Xiao H., McClements D.J. Delivery of lipophilic bioactives: assembly, disassembly, and reassembly of lipid nanoparticles. Annu Rev Food Sci Technol. 2014, 5:53-81.
159. Jamal-Hanjani M., Spicer J. Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of epidermal growth factor receptor-mutant non-small cell lung cancer metastatic to the brain. Clin Cancer Res 2012, 18(4):938-944.
160. Mathes T., Pieper D., Antoine S.-L., Eikermann M. Adherence influencing factors in patients taking oral anticancer agents: a systematic review. Cancer Epidemiol 2014, 38(3):214-226.
161. Loriot Y., Perlemuter G., Malka D., Penault-Llorca F., Penault-Lorca F., Boige V., et al. Drug insight: gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapy. Nat Clin Pract Oncol 2008, 5(5):268-278.
162. Schneider S.M., Adams D.B., Gosselin T. A tailored nurse coaching intervention for oral chemotherapy adherence. J Adv Pract Oncol 2014, 5(3):163-172.
163. Deng Y., Sychterz C., Suttle A.B., Dar M.M., Bershas D., Negash K., et al. Bioavailability, metabolism and disposition of oral pazopanib in patients with advanced cancer. Xenobiotica 2013, 43(5):443-453.
164. Roy S., Quiñones R., Matzger A.J. Structural and physicochemical aspects of dasatinib hydrate and anhydrate phases. Cryst Growth Des 2012, 12(4):2122-2126.
165. Grillo D., Polla G., Vega D. Conformational polymorphism on imatinib mesylate: grinding effects. J Pharm Sci 2012, 101(2):541-551.
166. Norges Helsedirektoratet. Scientific Discussion Sutent. <>, accessed [20.8.14]. http://www.helsedirektoratet.no.
167. Stopfer P., Marzin K., Narjes H., Gansser D., Shahidi M., Uttereuther-Fischer M., et al. Afatinib pharmacokinetics and metabolism after oral administration to healthy male volunteers. Cancer Chemother Pharmacol 2012, 69(4):1051-1061.
168. Chen Y., Tortorici M.A., Garrett M., Hee B., Klamerus K.J., Pithavala Y.K. Clinical pharmacology of axitinib. Clin Pharmacokinet 2013, 52(9):713-725.
169. Wind S., Giessmann T., Jungnik A., Brand T., Marzin K., Bertulis J., et al. Pharmacokinetic drug interactions of afatinib with rifampicin and ritonavir. Clin Drug Investig 2014, 34(3):173-182.
170. Abbas R., Hug B.A., Leister C., Burns J., Sonnichsen D. Effect of ketoconazole on the pharmacokinetics of oral bosutinib in healthy subjects. J Clin Pharmacol 2011, 51(12):1721-1727.
171. Karras S., Pontikides N., Krassas G.E. Pharmacokinetic evaluation of cabozantinib for the treatment of thyroid cancer. Expert Opin Drug Metab Toxicol 2013, 9(4):507-515.
172. Zimmerman E.I., Hu S., Roberts J.L., Gibson A.A., Orwick S.J., Li L., et al. Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res 2013, 19(6):1458-1466.
173. Chuan-Tang S., Nguyen L.N., Sparidans R.W., Wagenaar E., Beijnen J.H., Schinkel A.H. Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar. Int J Cancer 2014, 134(6):1484-1494.
174. Johnson F.M., Agrawal S., Burris H., Rosen L., Dhillon N., Hong D., et al. Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumors. Cancer 2010, 116(6):1582-1591.
175. Li J., Zhao M., He P., Hidalgo M., Baker S.D. Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. Clin Cancer Res 2007, 13(12):3731-3737.
176. Hamilton M., Wolf J.L., Drolet D.W., Fettner S.H., Rakhit A.K., Witt K., et al. The effect of rifampicin, a prototypical CYP3A4 inducer, on erlotinib pharmacokinetics in healthy subjects. Cancer Chemother Pharmacol 2014, 73(3):613-621.
177. Chen Y., Wang M., Zhong W., Zhao J. Pharmacokinetic and pharmacodynamic study of Gefitinib in a mouse model of non-small-cell lung carcinoma with brain metastasis. Lung Cancer 2013, 82(2):313-318.
178. Hu S., Franke R.M., Filipski K.K., Hu C., Orwick S.J., de Bruijn E.A., et al. Interaction of imatinib with human organic ion carriers. Clin Cancer Res 2008, 14(10):3141-3148.
179. Dutreix C., Peng B., Mehring G., Hayes M., Capdeville R., Pokorny R., et al. Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects. Cancer Chemother Pharmacol 2004, 54(4):290-294.
180. Castellino S., O'Mara M., Koch K., Borts D.J., Bowers G.D., MacLauchlin C. Human metabolism of lapatinib, a dual kinase inhibitor: implications for hepatotoxicity. Drug Metab Dispos 2012, 40(1):139-150.
181. Chan E.C.Y., New L.S., Chua T.B., Yap C.W., Ho H.K., Nelson S.D. Interaction of lapatinib with cytochrome P450 3A5. Drug Metab Dispos 2012, 40(7):1414-1422.
182. Novartis. Jakavi, Ruxolitinib. Prod Descr Novartis, 2014.
183. Gnoth M.J., Sandmann S., Engel K., Radtke M. In vitro to in vivo comparison of the substrate characteristics of sorafenib tosylate toward P-glycoprotein. Drug Metab Dispos 2010, 38(8):1341-1346.
184. Shibayama Y., Nakano K., Maeda H. Multidrug resistance protein 2 implicates anticancer drug-resistance to sorafenib. Biol Pharm Bull 2011, 34(3):433-435.
185. Lagas J.S., van Waterschoot R.A.B., Sparidans R.W., Wagenaar E., Beijnen J.H., Schinkel A.H. Breast cancer resistance protein and P-glycoprotein limit sorafenib brain accumulation. Mol Cancer Ther 2010, 9(2):319-326.
186. Kane R.C., Farrell A.T., Saber H., Tang S., Williams G., Jee J.M., et al. Sorafenib for the treatment of advanced renal cell carcinoma. Clin Cancer Res 2006, 12(24):7271-7278.
187. Shukla S., Robey R.W., Bates S.E., Ambudkar S.V. Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2. Drug Metab Dispos 2009, 37(2):359-365.
188. Arakawa-Todo M., Ueyama J., Nomura H., Abe F., Tsukiyama I., Matsuura K., et al. Drug interaction between sunitinib and cimetidine and contribution of the efflux transporter ATP-binding cassette C2 to biliary excretion of sunitinib in rats. Anticancer Res 2013, 33(8):3105-3111.
189. Jovelet C., Deroussent A., Broutin S., Paci A., Farinotti R., Bidart J.M., et al. Influence of the multidrug transporter P-glycoprotein on the intracellular pharmacokinetics of vandetanib. Eur J Drug Metab Pharmacokinet 2013, 38(3):149-157.
190. Martin P., Oliver S., Robertson J., Kennedy S.-J., Read J., Duvauchelle T. Pharmacokinetic drug interactions with vandetanib during coadministration with rifampicin or itraconazole. Drugs R D 2011, 11(1):37-51.
191. Durmus S., Sparidans R.W., Wagenaar E., Beijnen J.H., Schinkel A.H. Oral availability and brain penetration of the B-RAFV600E inhibitor vemurafenib can be enhanced by the P-GLYCOprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar. Mol Pharm 2012, 9(11):3236-3245.
192. Wu C.-P., Sim H.-M., Huang Y.-H., Liu Y.-C., Hsiao S.-H., Cheng H.-W., et al. Overexpression of ATP-binding cassette transporter ABCG2 as a potential mechanism of acquired resistance to vemurafenib in BRAF(V600E) mutant cancer cells. Biochem Pharmacol 2013, 85(3):325-334.
193. Escudier B., Gore M. Axitinib for the management of metastatic renal cell carcinoma. Drugs R D 2011, 11(2):113-126.
194. Abbas R., Leister C., Sonnichsen D. A clinical study to examine the potential effect of lansoprazole on the pharmacokinetics of bosutinib when administered concomitantly to healthy subjects. Clin Drug Investig 2013, 33(8):589-595.
195. Eley T., Luo F.R., Agrawal S., Sanil A., Manning J., Li T., et al. Phase I study of the effect of gastric acid pH modulators on the bioavailability of oral dasatinib in healthy subjects. J Clin Pharmacol 2009, 49(6):700-709.
196. Tawbi H.A., Tran A.L., Christner S.M., Lin Y., Johnson M., Mowrey E., et al. Calcium carbonate does not affect nilotinib pharmacokinetics in healthy volunteers. Cancer Chemother Pharmacol 2013, 72(5):1143-1147.
197. Egorin M.J., Shah D.D., Christner S.M., Yerk M.A., Komazec K.A., Appleman L.R., et al. Effect of a proton pump inhibitor on the pharmacokinetics of imatinib. Br J Clin Pharmacol 2009, 68(3):370-374.
198. Tan A.R., Gibbon D.G., Stein M.N., Lindquist D., Edenfield J.W., Martin J.C., et al. Effects of ketoconazole and esomeprazole on the pharmacokinetics of pazopanib in patients with solid tumors. Cancer Chemother Pharmacol 2013, 71(6):1635-1643.
199. Narasimhan N.I., Dorer D.J., Niland K., Haluska F., Sonnichsen D. Effects of food on the pharmacokinetics of ponatinib in healthy subjects. J Clin Pharm Ther 2013, 38(6):440-444.
200. Bello C.L., Sherman L., Zhou J., Verkh L., Smeraglia J., Mount J., et al. Effect of food on the pharmacokinetics of sunitinib malate (SU11248), a multi-targeted receptor tyrosine kinase inhibitor: results from a phase I study in healthy subjects. Anticancer Drugs 2006, 17(3):353-358.